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Background/aim: To detect the extent to which physical impairments are observed in patients with lung cancer awaiting lung surgery,
exercise capacity, muscle strength, physical activity, dyspnea, and quality of life (QOL) were objectively compared between the patients
and healthy individuals in current study.
Materials and methods: Patients with lung cancer (n = 26) and healthy individuals (n = 21) were included. Exercise capacity, respiratory
(maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP)) and quadriceps femoris muscle strength, physical activity,
dyspnea and QOL were evaluated using 6-min walk test (6-MWT), a mouth pressure device, a hand-held dynamometer, a metabolic
holter device, Modified Medical Research Council dyspnea scale and European Organization for Research and Treatment of Cancer
QOL Questionnaire C30 version 3.0, respectively.
Results: The 6-MWT distance (mean difference: 78.97 m), percentages of predicted MIP and MEP values, physical activity parameters
(energy expenditures, physical activity duration, average metabolic equivalent and number of steps) and QOL subscales scores
(functional, social function and global health status) were significantly lower in the patients than healthy individuals (p < 0.05). Dyspnea
perception and other QOL subscales scores (symptom and fatigue) were significantly higher in patients than healthy individuals (p <
0.05). No significant difference was prevalent in quadriceps femoris muscle strength (p > 0.05). Sixteen (66.7%) patients were sedentary.
Conclusion: Severe reductions in exercise capacity, respiratory muscle strength, and physical activity level, poorer QOL and evident
dyspnea exist in preoperative patients with lung cancer. Therefore, patients should be included in early protective rehabilitation program
including aerobic exercise, respiratory muscle training and physical activity counseling before lung surgery.
Key words: Lung neoplasms, walk test, dyspnea, muscle strength, exercise, quality of life

1. Introduction
Patients with lung cancer suffer from many
pathophysiological changes due to characteristics of lung
cancer and cytotoxic treatments including chemotherapy
and radiotherapy. These changes commonly occur in
respiratory mechanics and gas exchange mechanism,
all of which result in pulmonary function impairments.
Moreover, excessive weight loss, anemia, protein
catabolism, muscle wasting, skeletal muscle atrophy,
inhibition of muscle regeneration, reduced oxidative
capacity, and exercise intolerance are observed in patients
in course of time [1,2]. Progressive declines in exercise
capacity and muscle weakness are also commonly
observed in patients with lung cancer [2]. At the diagnosis
stage, 40% of the patients meet physical activity guidelines

requirements, and the patients are less physically active
than healthy individuals. This measurement did not
include any outcome regarding energy expenditure,
detailed amount and type of physical activity [2]. Based on
the limited studies, weakness in respiratory muscles before
surgery has been stated; however, there is no detailed
knowledge about predicted values representing patients’
characteristics to reveal differences [3,4]. Furthermore,
these patients experience fatigue and dyspnea, which
increase disease burden and afflict quality of life (QOL)
[5–7].
On the other hand, the detailed impairment levels
related with respiratory muscle strength and physical
activity have not yet been investigated along with
satisfactory and objective findings in preoperative patients
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with lung cancer in comparison with healthy individuals.
Therefore, to reveal impairments in these patients before
surgery is of importance in terms of being helpful in
both determining the early protective rehabilitation
program content and reducing the disease burden and
other possible factors. Aim of the current study was to
investigate differences in exercise capacity, respiratory and
peripheral muscle strength, physical activity level, dyspnea
and QOL between preoperative patients with lung cancer
and healthy individuals.
2. Materials and methods
2.1. Study design
This is a cross-sectional study that was performed at
cardiopulmonary rehabilitation unit of Gazi University,
Faculty of Health Sciences, Department of Physiotherapy
and Rehabilitation, Ankara, Turkey. All patients were
referred from Gazi University, Faculty of Medicine,
Department of Thoracic Surgery to the cardiopulmonary
rehabilitation unit. The Local Ethics Committee of Gazi
University approved this study (2019 - 250). Informed
consents were taken from each participant. This study
followed up the principles of Declaration of Helsinki.
2.2. Participants
The patients with lung cancer who were decided to
undergo lung surgery by thoracic surgeons were referred
to the physiotherapists. The patients were included based
on some inclusion criteria that were being a candidate for
lung surgery due to lung cancer diagnosis, between 18 and
80 years, clinically stable, able to walk and receiving optimal
medical therapy. The patients were excluded from the
study due to the following reasons: having health problems
such as cooperation, orthopedical or neurological diseases
that limited the walking ability and physical activity,
having comorbidities such as unstable diabetes mellitus,
heart failure, atrial fibrillation and/or hypertension, acute
infections or having myocardial infarction before study
at least six months. Healthy individuals were recruited
from relatives of the researchers and staff. These healthy
individuals were involved if they were between 18 and
80 years and willing to participate in the study. Though,
they were excluded from this study because of having any
chronic diseases. The patients were matched with healthy
individuals according to statistical similarity of both age
and sex.
2.3. Clinical characteristics
Charlson comorbidity index was used to score chronic
diseases accompanying primary disease, which shows
that mortality risk gradually increases as the total score
increases. Pulmonary risk assessment was performed
to determine the risk of developing postoperative
complications before surgery of which scores of 0 or 1
indicates a low pulmonary risk, and a score of ≥ 2 indicates
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a high pulmonary risk. Dynamic lung volumes were
measured using a spirometry (Cosmed, Class II/Internally
Powered Equipment, Italy).
2.4. Exercise capacity
Six-minute walk test (6-MWT) was performed to evaluate
exercise capacity according to the guidelines [8,9]. Heart
rate (PE3000 Polar Electro, Finland), blood pressures,
oxygen saturation (SpO2), breathing frequency, dyspnea,
and fatigue perceptions (Modified Borg scale) were
immediately recorded before and after tests. For the
statistical analysis, differences between post and pretest
values (∆) were calculated.
2.5. Muscle strength
Respiratory muscle weakness was detected using volitional
measurements of maximal inspiratory pressure (MIP) and
maximal expiratory pressure (MEP) via a portable mouth
pressure device (Micro Medical MicroRPM, England,
UK) based on guidelines. All individuals completed
both maximal inspiration against close airway for MIP at
residual volume and maximal expiration for MEP at total
lung capacity. The highest values for MIP and MEP were
recorded for analysis [10]. Reference values were used for
interpreting MIP and MEP measurements [11].
To evaluate quadriceps femoris muscle strength, a handheld dynamometer (JTECH Power Track Commander,
Baltimore, USA) was used. All individuals were tested by
experienced physiotherapists in sitting position with hips
and knees flexed at 90°, hands resting in lap and feet in the
air. The measurements were repeated from nondominant
side at least three times. The best value in Newton (N) was
recorded for analysis. Percentage of predicted value was
calculated using reference values [12].
2.6. Physical activity level
A metabolic holter device (SenseWear Armband Model
MF-SW, BodyMedia, Inc. Pittsburgh PA 15222, USA)
was used to obtain knowledge about total daily energy
expenditure (J / d), active energy expenditure (> 3
metabolic equivalents (METs)) (J / d), moderate and
severe physical activity duration (energy expended for
physical activity requiring > 3 METs) (min / d), number
of steps (steps / d), average metabolic equivalent (METs /
d), lying down (min / d) and sleeping duration (min / d)
[13]. The device was worn in the middle of nondominant
muscle body of triceps for two consecutive weekdays
[13]. Physical activity levels and intensity were classified
according to number of steps and METs [14,15].
2.7. Dyspnea
To evaluate the respiratory disability related with dyspnea,
the Modified Medical Research Council (MMRC) dyspnea
scale was used. Dyspnea levels are categorized between
0 (dyspnea only with strenuous exercise) and 4 (too
breathless to leave the house or when dressing/undressing)
[16].
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2.8. Quality of life
The European Organization for Research and Treatment
of Cancer QOL Questionnaire C30 version 3.0 (EORTC
QLQ-C30) was used. This is a self-administered
questionnaire which consists of five functional subscales
along with a social functioning subscale, three symptom
subscales with also a fatigue subscale, a global health
status subscale, and several single items. All item scores
are converted to values from 0 to 100. Higher values show
higher healthy levels in functional and social functioning
subscales, a higher QOL level in global health status
subscale, and increased presence of symptoms in both
symptom and fatigue subscales [17].
2.9. Statistical analyses
Sample size analysis prior to study (G*Power 3.0.10 system,
Franz Faul, Universität Kiel, Germany) was performed
to detect 6-MWT difference between two independent
means/groups for an α value of 0.05, effect size of 1.30,
95% power, and at least 17 participants for each group
were calculated [18]. Windows-based SPSS 15.0 statistical
analysis program was used (SPSS Inc., USA). To detect
normally distribution, variables were examined via visual
(histograms, probability plots) and analytical methods
(Shapiro-Wilk’s test). Variables were descriptively stated

as mean ± standard deviation (× ± SD), mean difference
between groups, 95% confidence interval (95%CI), median
(minimum-maximum (min-max)), U value, frequency (n)
and percentage (%). Student t test, Mann-Whitney U test
and Chi-square test were respectively used to compare
normally distributed, undistributed, and nominal variables
between the patients and healthy individuals. Level of
significance was set to p ≤ 0.05.
3. Results
Twenty-six patients with lung cancer and 21 healthy
individuals were compared as shown in Figure.
Demographic characteristics were similar in groups except
smoking exposure (p > 0.05, Table 1) and pulmonary
function test values were lower in the patients compared
with healthy individuals (p < 0.05). Clinical characteristics
of the patients were given in Table 2.
As shown in Table 3-6, 6-MWT distance, MIP%,
MEP%, physical activity parameters, functional subscale,
social function subscale, and global health status subscale
scores were significantly lower; MMRC dyspnea, symptom
subscale, and fatigue subscale scores were significantly
higher in the patients compared with healthy individuals
(p < 0.05).

Patients with lung cancer and
healthy individuals (n = 64)

Patients with lung
cancer (n = 38)

Exclusion reasons (n = 12)
Declined to participate (n = 5)
Age > 80 (n = 3)
Orthopedic problems (n = 3)

.
.
.
.

Healthy individuals
(n = 26)

Exclusion reasons (n = 5)
Not age-sex matched (n = 3)
Declined to participate (n = 2)

.
.

Fatality case (n = 1)

Patients with lung
cancer (n = 26)

Healthy individuals
(n = 21)

Figure. The follow diagram of patients with lung cancer and healthy individuals in the current study.
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Table 1. Demographic characteristics and pulmonary functions in patients with lung cancer and healthy individuals.
Patients with lung
cancer (n = 26)

Healthy individuals
(n = 21)

Characteristics

× ± SD / Median
(min – max)

× ± SD / Median
(min – max)

Mean difference (95%CI) / U p

Age (years)

61.85 ± 4.98

59.57 ± 5.75

2.27 (–0.88 to 5.43)

Female

4 / 15.4%

7 / 33.3%

Male

22 / 84.6%

14 / 66.7%

Height (cm)

166.96 ± 7.5

168.86 ± 8.66

–1.89 (–6.64 to 2.85)

0.425

Body weight (kg)

75 (47–115)

77 (66–103)

234.5

0.409

BMI (kg / m )

27.13 ± 3.97

27.67 ± 3.16

–0.54 (–2.69 to 1.61)

0.615

Cachexia

1 / 3.9%

0

Normal

7 / 26.9%

7 / 33.3%

Overweight

13 / 50%

7 / 33.3%

Obese

5 / 19.2%

7 / 33.3%

FEV1 (L)

2.13 ± 0.57

2.71 ± 0.66

–0.58 (–0.94 to –0.22)

0.002*

FEV1 (%)

75.88 ± 18.01

93.71 ± 16.85

–17.83 (–28.17 to –7.48)

0.001*

FVC (L)

2.91 ± 0.74

3.5 ± 0.85

–0.58 (–1.05 to –0.11)

0.016*

FVC (%)

83.81 ± 19.11

97.05 ± 15.75

–13.24 (–23.7 to –2.78)

0.014*

FEV1 / FVC (%)

72.3 ± 9.29

79.43 ± 8.92

–7.13 (–12.52 to –1.73)

0.011*

PEF (L)

6.02 ± 1.8

7.04 ± 2.2

–1.02 (–2.19 to 0.15)

0.087

PEF (%)

79.96 ± 20.89

94.9 ± 23.51

–14.94 (–27.99 to –1.89)

0.026*

FEF25-75% (L)

1.44 (0.55–4.47)

2.45 (0.98– 5.03)

114

0.001#

FEF25-75% (%)

49.92 ± 22.71

78.81 ± 29.9

–28.89 (–44.34 to –13.43)

< 0.001*

Smoker

5 / 19.2%

5 / 23.8%

Ex-smoker

16 / 61.6%

8 / 38.1%

Nonsmoker

5 / 19.2%

8 / 38.1%

40 (1–82.5)

7.5 (2–32)

0.153

Sex (n / %)

2

0.148

BMI classification (n / %)
0.452

Pulmonary function test

History of smoking (n / %)

Smoking (pack × year)

0.239
22

< 0.001#

*BMI: body mass index, FEV1: forced expiratory volume in the first second, FVC: forced vital capacity, FEV1/FVC: forced
expiratory volume in the first second/forced vital capacity, PEF: peak expiratory flow, FEF25–75%: forced expiratory flow from
25% to 75%, cm: centimeter, kg: kilogram, m: meter, L: liter, n: frequency, %: percentage, CI: confidence interval and U: U value.
**Descriptive analyses were presented using (× ± SD), median (min – max) and (n / %) for normally distributed, nonnormally
distributed and categorical variables, respectively.
***Student’s t-test *p < 0.05, Mann–Whitney U test #p < 0.05 and Chi square test ¥p < 0.05.

The 6-MWT distance was less than 80% of predicted
values in 14 (53.8%) patients and 1 (4.8%) healthy
individual. Inspiratory and expiratory muscle weakness
existed respectively in 5 (19.2%) and 11 (42.3%) patients; 2
(10%) and 4 (20%) healthy individuals. Quadriceps femoris
muscle strength was less than 80% of predicted values in
11 (42.3%) patients and 8 (38.1%) healthy individuals.
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Dyspnea in daily living activities was present in 10 (38.5%)
patients and 1 (4.8%) healthy individual.
4. Discussion
Our comprehensive results firstly provided compelling
evidence that there was a sharp distinction in terms of
dynamic lung volumes, exercise capacity (difference: 78.97
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Table 2. Clinical characteristics of patients with lung cancer.
Patients with
lung cancer
(n = 26)
Characteristics

× ± SD

Diagnoses (n / %)
Adenocarcinoma

11 / 42.3%

Squamous cell carcinoma

11 / 42.3%

Large cell carcinoma

1 / 3.9%

Other

3 / 11.5%

Pathological stage of lung cancer (n / %)
IA

7 / 26.9%

IB

2 / 7.7%

IIA

1 / 3.8%

IIB

4 / 15.4%

IIIA

6 / 23.1%

IV

6 / 23.1%

Tumor size (cm)

2.45 ± 1.37

Charlson Comorbidity Index score (0 -37)

2.73 ± 1

Very light (0) (n / %)

1 / 3.8%

Light (1– 2) (n / %)

10 / 38.5%

Heavy (3– 4) (n / %)

14 / 53.9%

Very heavy (≥ 5) (n / %)

1 / 3.8%

Pulmonary risk score (0 - 8)

2.04 ± 1.11

Low pulmonary risk (n / %)

10 / 38.5%

High pulmonary risk (n / %)

16 / 61.5%

Induction therapy (n / %)
No treatment

18 / 69.2%

Chemotherapy

6 / 23.1%

Radiotherapy

0 / 0%

Chemo-radiotherapy

2 / 7.7%

Surgery type (n / %)
Video-assisted thoracoscopic surgery

7 / 26.9%

Thoracotomy

19 / 73.1%

Pulmonary disease (n / %)

7 / 26.9%

Disease duration (month)

7.35 ± 7.57

*cm: centimeter, n: frequency, %: percentage.
**Descriptive analyses were presented using (× ± SD) and (n / %)
for normally distributed and categorical variables, respectively.

m), respiratory muscle strength, physical activity level,
dyspnea and QOL between patients with lung cancer and
healthy counterparts. Quadriceps femoris muscle strength
was interestingly preserved in patients. This study also

revealed the presence and prevalence of impairments
regarding decreased exercise capacity, inspiratory muscle
weakness, expiratory muscle weakness, increase in
dyspnea perception, and sedentary lifestyle in patients
with lung cancer awaiting surgery.
Six-MWT distance values of our patients were
considerably less than values of healthy counterparts.
Brocki et al. [19] showed that preoperative 6-MWT
distance values (506 m, 100%) are in normal ranges in
patients who scheduled for lung resection of lung cancer
[19]. Whereas 6-MWT distance value of these patients is
lower than our result, predictive value is higher than ours.
Study of Brocki et al. [19] also presented that 15 (19%)
patients had no malignancy, and the others were newly
diagnosed with lung cancer [19] which may have caused
relatively high predictive value for 6-MWT distance of
these patients compared to ours [19]. Disease durations
of our patients were about seven months. On the other
hand, after 6-month following diagnosis, progressive
reduction in 6-MWT distance (mean difference: 77.9 m,
from 84% of the predicted distance at the diagnosis stage
to 69% by 6-month) has been also shown in preoperative
patients with lung cancer following anticancer treatments
[2]. In fact, 30.4% of these patients had chronic
obstructive pulmonary disease [2]. Consistent with this
result, our study demonstrated that 6-MWT distance
was comparatively reduced (78.97 m) in preoperative
patients with lung cancer (26.9% had pulmonary disease)
whose disease duration was about 7-month. It is also
worth noting that there were no control groups in both
studies [2,19]. Morano et al. [20] investigated effects
of rehabilitation programs before lung surgery and
presented low 6-MWT distance (425 to 339 m) values in
both research groups [20]. Both our patients and healthy
individuals had higher 6-MWT distance values compared
to results of Morano et al.’s [20] study that have neither a
healthy group nor additional knowledge about predictive
value, disease duration or induction therapy status of the
patients. Another newly published study related effects of
pulmonary rehabilitation for inoperable patients with lung
cancer found that pre-rehabilitation 6-MWT distance of
patients (434.52 m) was 83.16% of predicted values [21].
These inoperable patients have walked lower distance
than our patients; however, the percentage of walked
distance was higher than ours. This may arise from using
different reference values [22]. Moreover, our patients
suffered from increased heart rate, breathing frequency,
and general fatigue along with decreased SpO2 before
6-MWT compared with healthy counterparts. Decreased
SpO2 and increased dyspnea perception were also evident
in our patients after 6-MWT. Unlike other studies, changes
in these physiological outcomes have been revealed in
current study. Given all results related with 6-MWT and
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Table 3. Comparison of exercise capacity in patients with lung cancer and healthy individuals.
Patients with lung
cancer (n = 26)

Healthy individuals
(n = 21)

× ± SD / Median
(min – max)

× ± SD / Median
(min – max)

Mean difference
(95%CI) / U

p

6-MWT (m)

529.34 ± 57.59

608.31 ± 61.1

–78.97 (–113.94 to –44.01)

< 0.001*

6-MWT (%)

79.72 (55.34 – 87.34) 91.39 (77.02 – 105.51)

50

< 0.001#

HR (beats / min)

86.31 ± 13.62

74.33 ± 11.71

11.97 (4.4 to 19.54)

0.003*

SBP (mmHg)

119.65 ± 12.04

124.14 ± 14.28

–4.49 (–12.22 to 3.24)

0.248

DBP (mmHg)

72.5 (60 – 100)

80 (68 – 90)

237

0.424

SpO2 (%)

96 (92 – 98)

97 (94 – 98)

177

0.034#

Breathing frequency (breaths / min)

24 (16 – 28)

20 (16 – 28)

147.5

0.004#

Dyspnea (MBS) (0 - 10)

0 (0 – 0.5)

0

252

0.199

General fatigue (MBS) (0 - 10)

0 (0 – 3)

0

199.5

0.011#

QFM fatigue (MBS) (0 - 10)

0 (0 – 3)

0

241.5

0.112

MaxHR (%)

82.16 (53.25 – 98.1)

74.85 (46.43 – 98.21)

186

0.063

∆ HR (beats / min)

42.85 ± 14.44

47.05 ± 18.23

-4.2 (-13.8 to 5.39)

0.383

∆ SBP (mmHg)

22.5 (-20 – 98)

20 (-15 – 60)

229

0.344

∆ DBP (mmHg)

0 (-12 – 22)

0 (-10 – 24)

255.5

0.700

∆ SpO2 (%)

-1.5 (-16 – 3)

0 (-5 – 3)

169.5

0.025#

∆ Breathing frequency (breaths / min)

4 (0 – 16)

4 (0 – 16)

255

0.685

∆ Dyspnea (MBS) (0 – 10)

0.75 (0 – 4)

0 (0 – 2)

166.5

0.010#

∆ General fatigue (MBS) (0 – 10)

0 (-1 – 4)

0 (0 – 3)

252.5

0.603

∆ QFM fatigue (MBS) (0 – 10)

0 (-0.5 – 5)

0 (0 – 2)

263.5

0.784

Exercise capacity

Resting values before 6-MWT

*6-MWT: 6-minute walk test, HR: heart rate, SBP: systolic blood pressure, DBP: diastolic blood pressure, SpO2: oxygen saturation, QFM:
quadriceps femoris muscle, maxHR: maximal heart rate, ∆: difference between post and pretest values, m: meter, %: percentage, min:
minute, mmHg: millimeter of mercury, MBS: modified Borg scale, CI: confidence interval and U: U value.
**Descriptive analyses were presented using (× ± SD) and median (min – max) for normally and nonnormally distributed variables,
respectively.
***Student’s t-test *p < 0.05 and Mann–Whitney U test #p < 0.05.

being a mortality predictor of decreased 6-MWT distance,
exercise capacity should be evaluated as soon as possible
following diagnosis. Then an appropriate aerobic exercise
training program should be initiated immediately.
Respiratory muscle weakness composes higher risk
for postoperative pulmonary complications in patients
undergoing thoracic surgery [23]. Predicted values of
respiratory muscle strength were decreased in our patients
(mean difference for MIP: –19.74% and MEP: –14.65 %)
compared to healthy individuals; however, MIP and
MEP mean values were in normal ranges. These results
should be concluded as; patients’ respiratory muscles
tend to weaken and should be followed during the course
of the time. Inspiratory (19.2%) and expiratory (42.3%)
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muscle weakness also existed in many of our patients.
The study without a healthy control group of Brocki et al.
[19] showed that MIP (85 cmH2O, 104%) and MEP (102
cmH2O, 106%) values were consistently in normal ranges
in newly diagnosed patients with lung cancer [19]. The
study of Morano et al. [20] also presented the lower MIP
and MEP values in patients, included in both pulmonary
rehabilitation and chest physical therapy programs [20].
These values were considerably lower than our results
and had no detailed knowledge about predicted values or
patients’ characteristics to reveal differences. On the other
hand, it has been known that patients with lung cancer
are physically inactive and do not exercise enough which
may contribute to many physical impairments and muscle
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Table 4. Comparison of respiratory and peripheral muscles strength and dyspnea in patients with lung cancer and healthy
individuals.
Patients with lung
cancer (n = 26)

Healthy individuals
(n = 21)

× ± SD / Median
(min – max)

× ± SD / Median
(min – max)

Mean difference
(95%CI) / U

p

MIP (cmH2O)

105.88 ± 22.56

119.3 ± 36.05

–13.41 (–32.19 to 5.36)

0.155

MIP (%)

103.83 ± 24.17

123.57 ± 32.27

–19.74 (–36.49 to –2.98)

0.022*

MEP (cmH2O)

156.38 ± 33.08

174.5 ± 48.58

–18.11 (–42.4 to 6.16)

0.140

MEP (%)

81.03 ± 14.74

95.67 ± 19.53

–14.65 (–24.82 to –4.47)

0.006*

MMRC dyspnea score (0 - 4)

0 (0 – 2)

0 (0 – 1)

179

0.007#

QFM strength (N) (ND)

346.46 ± 98.26

333.48 ± 84.93

12.98 (–41.72 to 67.69)

0.635

QFM strength (%) (ND)

86.36 ± 22.15

83.59 ± 20.1

2.77 (–9.79 to 15.33)

0.659

*MIP: maximal inspiratory pressure, MEP: maximal expiratory pressure, MMRC: Modified Medical Research Council, %:
percentage, cmH2O: centimeter of water, ND: nondominant, N: newton, CI: confidence interval and U: U value.
**Descriptive analyses were presented using (× ± SD) and median (min – max) for normally and nonnormally distributed
variables, respectively.
***Student’s t-test *p < 0.05 and Mann–Whitney U test #p < 0.05.

Table 5. Comparison of physical activity levels in patients with lung cancer and healthy individuals.
Patients with lung
cancer (n = 26)

Healthy individuals
(n = 21)

× ± SD / Median
(min – max)

× ± SD / Median
(min – max)

Mean difference
(95%CI) / U

p

Total energy expenditure (J / d)

8918.29 ± 2684.21

11056.38 ± 1676.5

–2138.09
(–3507.08 to –769.09)

0.003*

Active energy expenditure (> 3 METs) (J / d)

1068 (71 – 4809)

1955 (353 – 5681)

149

0.019#

Physical activity duration (> 3 METs) (min / d)

56.5 (3 – 216)

106 (21 – 299)

148.5

0.019#

Average metabolic equivalent (METs / d)

1.2 (0.9 – 1.9)

1.4 (1.2 – 1.8)

152.5

0.022#

Sedentary (n / %)

22 / 91.7%

16 / 76.2%

Light-intensity (n / %)

2 / 8.3%

5 / 23.8%

3821.5 (152 – 15951)

8828 (2446 – 17307)

Sedentary (n / %)

16 / 66.7%

5 / 23.8%

Low active (n / %)

4 / 16.6%

3 / 14.3%

Somewhat active (n / %)

1 / 4.2%

5 / 23.8%

Active (n / %)

1 / 4.2%

3 / 14.3%

Highly active (n / %)

Physical activity parameters

Number of steps (steps / d)

0.225
121

0.003#

0.030¥

2 / 8.3%

5 / 23.8%

Lying down (min / d)

506.87 ± 158.05

437.24 ± 128.91

69.64 (-17.88 to 157.15) 0.116

Sleep duration (min / d)

393 (165 – 1440)

368 (171 – 586)

186.5

0.136

*J: joule, d: day, min: minute, MET: metabolic equivalent, n: frequency, %: percentage, CI: confidence interval and U: U value.
**Descriptive analyses were presented using (× ± SD), median (min – max) and (n / %) for normally distributed, nonnormally distributed
and categorical variables, respectively.
***Student’s t-test *p < 0.05, Mann–Whitney U test #p < 0.05 and Chi square test ¥p < 0.05.
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Table 6. Comparison of quality of life in patients with lung cancer and healthy individuals.
Patients with lung cancer
(n = 26)

Healthy individuals
(n = 21)

Median (min – max)

Median (min – max)

U

p

Functional subscale (0 - 100%)

90 (55.56 – 100)

97.78 (64.44 – 100)

144

0.005#

Social function subscale (0 - 100%)

100 (33.33 – 100)

100 (66.67 – 100)

193

0.017#

Symptom subscale (0 - 100%)

7.69 (0 – 41.03)

0 (0 – 20.51)

133

0.002#

Fatigue subscale (0 - 100%)

11.11 (0 – 77.78)

0 (0 – 55.56)

190

0.051#

Global health status subscale (0 - 100%)

75 (41.67 – 100)

83.33 (58.33 – 100)

180.5

0.044#

EORTCQLQ-C30 subscales scores

*EORTCQLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, %:
percentage, CI: confidence interval and U: U value.
**Descriptive analyses were presented using median (min – max) for nonnormally distributed variables.
***Mann–Whitney U test #p < 0.05.

weakness [24]. Our study has a superiority in terms of
having a control group and detailed predictive values
which may be used to predict the risk for postoperative
pulmonary complications such as prolonged mechanical
ventilation etc. in patients undergoing thoracic surgery
due to lung cancer. However, there are both scarce and
conflicting results regarding respiratory muscle strength in
the literature. Therefore, further investigations are needed.
Loss of skeletal muscle mass and strength is related
with the risk of perioperative complications and worse
long-term survival rates in patients with lung cancer
undergoing lung surgery [25]. Quadriceps femoris muscle
strength was preserved in our patients, 30.8% to whom
induction therapy were given and disease durations
were approximately 7 months. However, 11 (42.3%)
patients had weakness in quadriceps femoris muscle in
current study. In contradiction to our results, Granger et
al. [2] demonstrated that patients newly diagnosed with
nonsmall cell lung cancer have impaired quadriceps
femoris muscle strength (18.8 versus 23.7 kg) than
healthy individuals [2]. The results of Granger et al. [2]
presented much decreased results in muscle strength than
the present study. The difference reasons may be derived
from some characteristics of this study [2] that are the
inclusion of patients with only nonsmall cell cancer and
older age of the patients (68.5 years) compared to ours.
Similar to study of Granger et al. [2], Hummler et al. [18]
demonstrated common weakness in upper and lower
extremity muscles of patients with advanced stage lung
cancer who had no surgery history compared to healthy
reference data. Naito et al. [26] also found skeletal muscle
depletion (evaluated using lumbar skeletal muscle index
and hand grip strength) and physical functional decline in
the early phase of chemotherapy in elderly patients with
lung cancer. The loss of muscle mass is associated with
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an increase in protein catabolism. Increased expression
of components in the ubiquitin-proteasome proteolytic
pathway and decreased protein production cause a decline
in muscle and muscle fiber cross-sectional area which is
resulted in loss of muscle extensibility and strength [27].
If we also consider the tendency to weaken of muscle
strength seen in our patients, both respiratory and
peripheral muscles strength, which predict perioperative
complications, should be evaluated and strengthened in
patients with lung cancer.
Our study results demonstrated that total and
active energy expenditures, physical activity duration,
average metabolic equivalent and number of steps were
substantially decreased in the patients. Moreover, 66.7% of
our patients adopted sedentary lifestyle. Consistent with
our results, Granger et al. [2] showed that only 40% of
patients with newly diagnosed lung cancer meet physical
activity guidelines at the diagnosis stage, and the patients
are less physically active than healthy individuals [2].
Moreover, Edbrooke et al. [28] demonstrated that number
of steps per day is considerably decreased in inoperable
patients with newly diagnosed lung cancer [28]. As seen,
patients with lung cancer mostly adopt both sedentary
lifestyle and walk less in a day from the diagnosis stage.
This may cause many deteriorations regarding muscle
weakness and exercise intolerance; increase in symptoms
such as fatigue and dyspnea and impairment in QOL [24].
Therefore, these patients should be directed to physical
activity counseling as soon as possible since all dimensions
including energy expenditure and number of steps, type
and duration of physical activity are affected in these
patients, which has been shown in our comprehensive
study.
Based on present study results, both exertional
dyspnea and dyspnea in daily living activities (38.5%)
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were evident in the patients compared with healthy
individuals. The study without a healthy group of Brocki
et al. [19] (19% of patients had no malignancy and 81%
were diagnosed as lung cancer) consistently showed that
mean of dyspnea evaluated using Borg scale was two units
in the patients. There is a scarcity regarding investigating
the dyspnea in patients with lung cancer in the literature,
therefore current study presents valuable contribution
to the literature. Because these results show that patients
with lung cancer suffer from both exertional dyspnea and
dyspnea in daily living activities, which is possible to be
improved via inspiratory muscle training, frequently used
in rehabilitation clinics, while awaiting surgery.
Both all aspects of QOL were impaired and the
symptoms related with lung cancer were increased in
patients with lung cancer awaiting lung surgery in current
study. In consistent with our results, Hummler et al. [18]
demonstrated that poorer QOL exists in patients with
advanced stage lung cancer who had no surgery history
compared to healthy reference data. Granger et al. [2]
also demonstrated that at the diagnosis stage, the patients
with lung cancer have worse mood and QOL compared
to healthy individuals. After six months, these patients
experience worsening symptoms following chemotherapy,
radiotherapy and/or surgery [2]. As a result, patients with
lung cancer are exposed to a long-lasting QOL impairment
after surgery and/or chemotherapy, radiotherapy which
should be followed up in these patients.
5. Conclusion
Given that our results firstly showed both sharp reduction
in dynamic lung volumes, exercise capacity, respiratory

muscle strength, physical activity level, and QOL and
increase in dyspnea perception, and the symptoms in
preoperative patients with lung cancer, it is of importance
to evaluate these patients before surgery. Of importance
patients’ well-being, patients in the preoperative phase
should be involved in rehabilitation programs including
aerobic exercise, respiratory muscle training, and physical
activity counseling. After surgery, patients should also be
followed to observe changes in these outcomes in terms
of applying appropriate rehabilitation approaches during
whole process.
6. Limitations
The gold standard method for the evaluation of exercise
capacity and dyspnea perception is cardiopulmonary
exercise testing, but it could not be performed due
to technical problems, which should better be used
in further studies. Hand-held dynamometer use, to
evaluate isometric quadriceps femoris muscle strength,
is commonly based on practitioner’s muscle strength.
Therefore, if possible, using isokinetic system, which is
a gold standard technique for isokinetic muscle strength
evaluation, should be considered in future studies.
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